50P DLL3 expression by immunohistochemistry in rare neuroendocrine neoplasms and associated response to off label tarlatamab
Tarlatamab, a DLL3-directed bispecific T-cell engager, is approved for relapsed small cell lung cancer (SCLC). Delta-like ligand 3 (DLL3) is also expressed in a range of neuroendocrine neoplasms (NENs), offering a promising precision medicine target beyond SCLC. We evaluated the efficacy and safety of tarlatamab in patients with rare NENs and explored the relationship between DLL3 expression and antitumor response.
Authors
- T. Schieber
- P. Neupane
- C.H. Huang
- J. Campaign-Mauser
- R. Parikh
- B. Gustafson
- D. Kim
- S. Mullangi
- H. Li
- B. Bortka
- A. Olinger
- J. Zhang
- J. Hobbs
- M.R. Lekkala
- E. Jones
- S. Blocker
Institutions
- Saint Luke's Health System (US)
- Avera Health (US)
- Huntsman Cancer Institute (US)
- The University of Kansas Cancer Center (US)
- University of Kansas Medical Center (US)
- Saint Luke's Hospital (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101133
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00